Gema Requena

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Venues

International journal of chronic obstructive pulmonary disease

BMJ open

Pharmacoepidemiology and drug safety

Clinical drug investigation

GlaxoSmithKline

Universidad de Alcalá de Henares Facultad de Medicina y Ciencias de la Salud (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GlaxoSmithKline

United Kingdom

Manager Epidemiology :: Real World Evidence & Epidemiology

Education History

Universidad de Alcalá de Henares Facultad de Medicina y Ciencias de la Salud

Spain

PHD :: Pharmacology

London School of Hygiene and Tropical Medicine

United Kingdom

MSC

Publications

Alexandrosz Czira, Victoria L Banks, Gema Requena, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B 2 -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ open 14 (2) (2024)
Claus F Vogelmeier, Kai-Michael Beeh, Michael Schultze, Nils Kossack, Lena M Richter, Jing Claussen, Chris Compton, Stephen G Noorduyn, Afisi S Ismaila, Gema Requena
Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study. International journal of chronic obstructive pulmonary disease 19 (2024)
Claus F Vogelmeier, Kai-Michael Beeh, Michael Schultze, Nils Kossack, Lena M Richter, Jing Claussen, Chris Compton, Stephen G Noorduyn, Afisi S Ismaila, Gema Requena
Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study. International journal of chronic obstructive pulmonary disease 19 (2024)
Alexandrosz Czira, Victoria L Banks, Gema Requena, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B 2 -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ open 14 (2) (2024)
Alexandrosz Czira, Victoria L Banks, Gema Requena, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B 2 -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ open 14 (2) (2024)
Alexandrosz Czira, Victoria L Banks, Gema Requena, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B 2 -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ open 14 (2) (2024)
Alexandrosz Czira, Victoria L Banks, Gema Requena, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B 2 -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ open 14 (2) (2024)
Alexandrosz Czira, Gema Requena, Victoria L Banks, Robert P Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie A C Wild, Chris Compton, Kieran J Rothnie, Felix J F Herth, Jennifer Kathleen Quint, Afisi S Ismaila
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β 2 -Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Gema Requena, Sandra Joksaite, Nicholas Galwey, Rupert Jakes W
An algorithm-based approach to ascertain patients with rare diseases in electronic health records using hypereosinophilic syndrome as an example. Pharmacoepidemiology and drug safety (2023)
Gema Requena, Alexandrosz Czira, Victoria L Banks, Robert P Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie A C Wild, Chris Compton, Kieran J Rothnie, Felix J F Herth, Jennifer Kathleen Quint, Afisi S Ismaila
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Gema Requena, Alexandrosz Czira, Victoria L Banks, Robert P Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie A C Wild, Chris Compton, Kieran J Rothnie, Felix J F Herth, Jennifer Kathleen Quint, Afisi S Ismaila
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Gema Requena, Victoria L Banks, Alexandrosz Czira, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β 2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Alexandrosz Czira, Gema Requena, Victoria L Banks, Robert P Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie A C Wild, Chris Compton, Kieran J Rothnie, Felix J F Herth, Jennifer Kathleen Quint, Afisi S Ismaila
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β 2 -Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Gema Requena, Victoria L Banks, Alexandrosz Czira, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Afisi S Ismaila
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β 2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. International journal of chronic obstructive pulmonary disease 18 (2023)
Gema Requena, Victoria L Banks, Alexandrosz Czira, Robert P Wood, Theo Tritton, Rosie A C Wild, Chris Compton, Maria Duarte, Afisi S Ismaila
Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β 2 -Agonist Dual Therapy in a Primary Care Setting in England. International journal of chronic obstructive pulmonary disease 17 (2022)
Gema Requena, Achim Wolf, Rachael Williams, Daniel Dedman, Jennifer K Quint, Tarita Murray-Thomas, Jeanne M Pimenta
Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials. Pharmacoepidemiology and drug safety 30 (4) (2021)
Gema Requena, John Logie, Daniel C Gibbons, Jonathan Steinfeld, Melissa K Van Dyke
The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom. Immunity, inflammation and disease 9 (4) (2021)
Gema Requena, Florence Roufosse, Lee D Baylis, Jonathan Steinfeld
Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab. Respirology case reports 9 (2) (2021)
Gema Requena, Liyuan Ma, Til Stürmer, J Bradley Layton, Julia DiBello
Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clinical drug investigation 40 (8) (2020)

Gema Requena.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Gema Requena